Revenues

12 Months Ended

Dec. 31, 2020

Revenue from Contract with Customer [Abstract]

REVENUES

Disaggregation of Revenues

Revenues were as follows:


	Year Ended December 31, 2020								Year Ended December 31, 2019								Year Ended December 31, 2018
(in millions)	U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total		U.S.		Europe		Other International		Total
Product Sales:
HIV Products
Atripla	$	307	$	21	$	21	$	349	$	501	$	60	$	39	$	600	$	967	$	131	$	108	$	1,206
Biktarvy	6,095		735		429		7,259		4,225		370		143		4,738		1,144		39		1		1,184
Complera/Eviplera	89		159		21		269		160		214		32		406		276		327		50		653
Descovy	1,526		197		138		1,861		1,078		255		167		1,500		1,217		308		56		1,581
Genvoya	2,605		490		243		3,338		2,984		664		283		3,931		3,631		794		199		4,624
Odefsey	1,172		450		50		1,672		1,180		438		37		1,655		1,242		335		21		1,598
Stribild	125		54		17		196		268		75		26		369		505		97		42		644
Truvada	1,376		27		45		1,448		2,640		101		72		2,813		2,605		260		132		2,997
Other HIV (1)	25		5		28		58		30		5		12		47		40		7		14		61
Revenue share - Symtuza (2)	331		149		8		488		249		130		—		379		27		52		—		79
Total HIV product sales	13,651		2,287		1,000		16,938		13,315		2,312		811		16,438		11,654		2,350		623		14,627
Hepatitis C virus (“HCV”) Products
Ledipasvir/Sofosbuvir (3)	92		29		151		272		312		71		260		643		802		144		276		1,222
Sofosbuvir/Velpatasvir (4)	864		337		398		1,599		971		553		441		1,965		934		654		378		1,966
Other HCV (5)	132		48		13		193		182		118		28		328		287		98		113		498
Total HCV product sales	1,088		414		562		2,064		1,465		742		729		2,936		2,023		896		767		3,686

Veklury	2,026		607		178		2,811		—		—		—		—		—		—		—		—

Cell Therapy Products
Yescarta	362		191		10		563		373		83		—		456		263		1		—		264
Tecartus	34		10		—		44		—		—		—		—		—		—		—		—
Total Cell Therapy product sales	396		201		10		607		373		83		—		456		263		1		—		264

Trodelvy	49		—		—		49		—		—		—		—		—		—		—		—

Other Products
AmBisome	61		230		145		436		37		234		136		407		46		229		145		420
Letairis	314		—		—		314		618		—		—		618		943		—		—		943
Ranexa	9		—		—		9		216		—		—		216		758		—		—		758
Vemlidy	356		29		272		657		309		21		158		488		245		12		64		321
Viread	14		34		137		185		32		69		142		243		50		82		175		307
Zydelig	31		39		2		72		47		54		2		103		61		70		2		133
Other (6)	146		53		14		213		153		52		9		214		154		56		8		218
Total Other product sales	931		385		570		1,886		1,412		430		447		2,289		2,257		449		394		3,100
Total product sales	18,141		3,894		2,320		24,355		16,565		3,567		1,987		22,119		16,197		3,696		1,784		21,677
Royalty, contract and other revenues	76		241		17		334		80		244		6		330		72		310		68		450
Total revenues	$	18,217	$	4,135	$	2,337	$	24,689	$	16,645	$	3,811	$	1,993	$	22,449	$	16,269	$	4,006	$	1,852	$	22,127

_______________________________

(1) Includes Emtriva and Tybost.

(2) Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.

(3) Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4) Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5) Includes Vosevi and Sovaldi.

(6) Includes Cayston, Hepsera and Jyseleca.

Revenues From Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues:


	Year Ended December 31,
(as a percentage of total revenues)	2020		2019		2018
AmerisourceBergen Corporation	27	%	21	%	20	%
Cardinal Health, Inc.	21	%	21	%	21	%
McKesson Corporation	20	%	22	%	21	%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $841 million and $741 million for the years ended December 31, 2020 and 2019, respectively.

Variable consideration is included in the net sales price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable of occurring when the uncertainty associated with the variable consideration is subsequently resolved. Estimates are assessed each period and updated to reflect current information. Changes in estimates for variable consideration related to sales made in prior years resulted in a $101 million increase and a $257 million increase in revenues for the years ended December 31, 2020 and 2019, respectively.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $198 million and $144 million as of December 31, 2020 and 2019, respectively. Contract liabilities were $97 million and $45 million as of December 31, 2020 and 2019, respectively. During 2020 and 2019, revenue recognized that was included in the contract liability balance as of the beginning of the respective years was not material. Revenue expected to be recognized in the future from contract liabilities as the related performance obligations are satisfied is not expected to be material in any one year.